🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. Tenofovir gel

    United Therapeutics Europe Ltd

    HIV Infections

    phase 2 small molecule completed

    1 trial

  2. Tevimbra 100 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh B, ALBI grade 1 or 2 liver function, pretreated or not by tyrosine kinase inhibitors and not pretreated with immunotherapy.

    phase 2 small molecule active

    1 trial

  3. The Placebo composition is the same of the IMP except the active ingredient

    Fondazione Telethon ETS

    Optic Pathway Glioma (OPG)

    phase 2 small molecule active

    1 trial

  4. The corresponding placebo solution consists of the 25 nM phosphate buffer solution with 4 μg of vitamin B2 added for colouring purposes only., RBD1016, Vemlidy 25 mg film-coated tablets.

    Lacuna Pharma Pty Ltd

    Chronic hepatitis D virus infection

    phase 2 small molecule active

    1 trial

  5. The placebo is the same as the ensifentrine suspension except that the active ensifentrine ingredient is omitted (i.e., it consists of phosphate buffered saline and surfactants only); it is also supplied as a single unit-dose LDPE translucent ampule overwrapped in a foil pouch, Ensifentrine inhalation suspension

    Lacuna Pharma Pty Ltd

    Non-Cystic Fibrosis Bronchiectasis

    phase 2 small molecule active

    1 trial

  6. The placebo used the same excipients as that used in IMP without active drug substance. The placebo was developed as film-coated tablet same in size and appearance to the IMP., BRENSOCATIB, BRENSOCATIB

    Insmed Limited

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

  7. The placebo will consist solely of the excipients of eblasakimab, i.e., the same formulation without the active ingredient and will be identical in appearance to eblasakimab. Pharmaceutical form: Solution for SC injection

    Lacuna Pharma Pty Ltd

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  8. Theory-based counseling program

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 2 other completed

    1 trial

  9. Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections

    The First People's Hospital of Lianyungang

    Hematological Malignancy

    phase 2 small molecule active

    1 trial

  10. Tiotropium HFA BAI 5 mcg

    Teva Pharma GmbH

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule terminated

    1 trial

  11. Tipranavir

    Boehringer Ingelheim

    HIV Infections

    phase 2 small molecule completed

    1 trial

  12. Tovinontrine, Tovinontrine, Tovinontrine, tovinontrine-matching placebo, immediate-release tablet

    Lacuna Pharma Pty Ltd

    Heart failure (HF) with reduced ejection fraction (HFrEF)

    phase 2 small molecule active

    1 trial

  13. Tranexamic Acid

    United Therapeutics Europe Ltd

    Anterior Cruciate Ligament Reconstruction

    phase 2 small molecule active

    1 trial

  14. Tumor Intiltrating Lymphocytes (TIL) – VHIO, Fludarabina Teva 25 mg/ml concentrado para solución para perfusión o inyección EFG, Melanoma Tumor Intiltrating Lymphocytes (TIL) – NKI, Fludarabine - PCH 25 mg/ml, concentraat voor oplossing voor intraveneuze infusie of injectie, ANV419, Fludarabinphosphat "Ebewe", koncentrat til injektions-/infusionsvæske, opløsning, Genoxal 1.000 mg polvo para solución inyectable y para perfusión, PROLEUKIN, 18x106 UI polvo para solución inyectable o para perfusión, PROLEUKIN®

    The George Institute

    Advanced selected solid tumors: melanoma, non-small cell lung cancer (NSCLC) and cervical cancer.

    phase 2 small molecule active

    1 trial

  15. Tumour heterogeneity studies based on dedicated breast PET using proliferation radiotracers: early detection of the treatment response.

    The George Institute

    Breast cancer

    phase 2 other active

    1 trial

  16. Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab completed

    1 trial

  17. Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab completed

    2 trials

  18. Tyenne 162 mg solution for injection in pre-filled pen

    Cardiff Oncology

    Psoriatic Arthritis, Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  19. Tyenne 162 mg solution for injection in pre-filled pen

    Cardiff Oncology

    Psoriatic Arthritis, Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  20. UB-421

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HIV-1-infection

    phase 2 mab active

    1 trial

  21. UB-421(25 mg/kg) Q2W

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HIV-1-infection

    phase 2 mab active

    1 trial

  22. UB-421(25 mg/kg) Q2W

    United Therapeutics Europe Ltd

    HIV-1 Infection

    phase 2 mab completed

    1 trial

  23. UBT251

    United Therapeutics Europe Ltd

    Metabolic Dysfunction-associated Steatohepatitis (MASH)

    phase 2 small molecule active

    1 trial

  24. UBT251 Injection 2.0 mg and UBT251 Injection Placebo

    United Therapeutics Europe Ltd

    Obesity &Amp; Overweight

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources